Introduction
============

Chemokines are an important superfamily of chemoattractant cytokines mediating directional leukocyte migration in innate and acquired host defense responses in a concentration-dependent manner. Through interaction of basic amino acid residues in the chemokine carboxyl-terminal α-helix with negatively charged glycosaminoglycans (GAGs)[^3^](#FN4){ref-type="fn"} of proteoglycans in the extracellular matrix or on cells, chemokines form a haptotactic gradient, the slope of which directs leukocyte migration ([@B1], [@B2]). There are four subfamilies of chemokines based upon the proximity of the conserved amino-terminal cysteine (C) residues, the largest being the CC and CXC subfamilies. Chemokines exert activity by binding to receptors on leukocyte surfaces; CC chemokines bind to CC receptors (CCRs), whereas CXC chemokines bind CXCRs. The predominant CXCRs, namely CXCR1 and CXCR2, are expressed by neutrophils with monocytes expressing CCR1, CCR2, CCR3, CCR5, and CCR8 ([@B3], [@B4]). The flexible amino terminus of a chemokine is involved in binding and activating its cognate receptor ([@B5], [@B6]). Receptor activation causes intracellular signaling, including calcium mobilization, resulting in cell activation that is characterized by cell migration, gene transcription, relocation of receptors to the cell membrane, and the release of further inflammatory mediators. Inappropriate continual recruitment and activation of leukocytes can result in tissue damage in chronic inflammatory diseases such as rheumatoid arthritis. Thus, regulation of cellular recruitment and termination of this intercellular signaling is critical to both initiate and then later dampen inflammatory responses.

Post-translational modifications of both the amino and carboxyl termini of chemokines by proteolytic processing is a versatile mechanism of regulation, trimming CXC chemokines into stronger agonists for recruitment of neutrophils, of both CXC and CC chemokines to receptor antagonists to terminate signaling, to switch receptor use, and to shed CX3CL1 or, alternatively, to modify the GAG binding site to prevent or disrupt haptotactic gradient formation ([@B7]--[@B19]).

A number of chemokines are processed *in vitro* by proteases and in particular by serine proteases from neutrophils and by matrix metalloproteinases (MMPs) ([@B8], [@B12], [@B13], [@B20]--[@B29]). Serine proteases, including cathepsin G and neutrophil elastase, are secreted by activated neutrophils during an inflammatory response; natural inhibitors include serpins. MMPs are an important family of extracellular endopeptidases that are up-regulated in stimulated stromal cells and leukocytes and are pathognomonic of many chronic inflammatory diseases. The activity of MMPs is regulated by tissue inhibitors of metalloproteinases (TIMPs) with the net individual activities of different MMPs being both beneficial and detrimental in disease ([@B30]).

In the CXC chemokine subfamily the neutrophil chemoattractants CXCL8 and CXCL5 are processed, in particular by the neutrophil-specific MMP-8 (also known as collagenase-2), to become potent receptor agonists and form a feed-forward mechanism, a critical step for neutrophil recruitment ([@B16], [@B27]). In contrast, all seven neutrophil CXC agonists in man are inactivated by macrophage-derived MMP-12, terminating the recruitment of neutrophils ([@B21]). Multiple MMPs generate potent CCR1, CCR2, and CCR5 receptor antagonists by cleaving CCL2, -7, -8, and -13 to terminate monocyte recruitment ([@B12], [@B13]). Notably, proteolysis of human CC chemokines that results in an activating cleavage is limited to serine protease activity on CCL4 ([@B31]), CCL14 ([@B32]--[@B34]), CCL15 ([@B20]), and CCL23 ([@B20]).

In an *in vitro* assay, the 92-amino acid residue CCL15-(1--92) and the 99 amino acid residue CCL23-(1--99), neither of which is a potent chemoattractant in the full-length form ([@B35], [@B36]), were processed by synovial fluid from arthritic patients to the products CCL15-(25--92) and CCL23-(19--99) that have enhanced CCR1 agonist activity ([@B20]). However, despite the importance of this observation, the specific proteases responsible for these cleavages could not be identified despite considerable effort. Amino-terminally truncated CCL15 and CCL23 were both identified in synovial fluid from arthritic patients at concentrations of 10--100-fold that of CCL3 and CCL5 ([@B20]), indicating that these truncated chemokines may contribute to the cellular recruitment that is observed in chronic inflammation.

Herein we utilized inhibitors to identify the protease classes responsible for the activating cleavages of CCL15 in synovial fluid, finding that both serine proteases and MMPs are responsible. In view of the importance of macrophage recruitment, this encouraged us to identify other MMP chemokine substrates. Therefore, we performed a global evaluation of MMP processing of all 14 CC chemokines that are involved in monocyte recruitment. We report that MMP processing of the long amino-terminal CCL15 and CCL23 chemokines and the long carboxyl-terminal CCL16, notably by the monocyte/macrophage specific MMP-12, results in increased receptor activation or GAG binding, respectively. These data thereby point to a critical role for MMPs in the promotion and regulation of monocyte recruitment. Our results implicate new feed-forward mechanisms whereby macrophage and synovial fluid proteases promote the recruitment of monocytes, potentiating the inflammatory response.

EXPERIMENTAL PROCEDURES
=======================

### 

#### Proteinases and Chemokines

Recombinant human MMPs 1, 2, 3, 8, 9, 12, 13, and soluble MMP-14 were expressed and purified ([@B37]). MMP-7 was from U. S. Biochemical Corp. All full-length chemokines were chemically synthesized using *t*-butoxycarbonyl solid phase chemistry, purified by high performance liquid chromatography, and validated for activity as described ([@B38]). A 19-mer peptide corresponding to CCL23-(5--23) was chemically synthesized by Sigma. CCL15-(25--92, 28--92), CCL16-(8--77, 8--85), and CCL23-(26--99), utilized for *in vitro* experiments, were the fully truncated products of MMP-12 cleavage of full-length counterparts; these preparations lack full-length chemokine as determined by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (MS). Controls for functional assays, namely full-length chemokine and MMP-12 alone, were prepared at the same time.

#### Chemokine Cleavage in Synovial Fluid

Cleavage of 2.5 μg of CCL15-(1--92) in 0.25 μg of synovial fluid pooled from eight rheumatoid arthritis patients was performed at 37 °C for 16 h in cleavage assay buffer in the absence or presence of 1 m[m]{.smallcaps} PMSF (general serine proteinase inhibitor), 10 μ[m]{.smallcaps} marimastat (small molecule general metalloproteinase inhibitor) ([@B39]), 100 μ[m]{.smallcaps} TIMP-1 and TIMP-2 (endogenous metalloproteinase inhibitors), 10 μ[m]{.smallcaps} E64 (cysteine protease inhibitor), 10 μ[m]{.smallcaps} pepstatin (aspartyl protease inhibitor), and 100 μ[m]{.smallcaps} leupeptin (inhibitor of specific serine and cysteine proteases) either alone or in combination. Cleavage of CCL15 in the synovial fluid was assessed as described ([@B40]) by MALDI-TOF MS on a Voyager-DE STR (Applied Biosystems) or a 4700 tandem mass spectrometer (Applied Biosystems) using the matrices sinapic acid or α-cyano-4-hydroxycinnamic acid, respectively, and confirmed by silver-staining after 15% Tris-Tricine SDS-PAGE.

#### Chemokine Cleavage Assays

Zymogen forms of MMP-1, -2, -8, -9, -13, and -14 were activated by incubation with 1 m[m]{.smallcaps} *p*-aminophenylmercuric acetate for 45 min at 37 °C. The recombinant MMP-7 and -12 lacked a prodomain and so did not require activation. MMP-3 was activated by incubation with 0.25 μ[m]{.smallcaps} chymotrypsin for 30 min at 37 °C, and then the chymotrypsin activity was inhibited by the addition of 1 m[m]{.smallcaps} PMSF; all experiments with MMP-3 included a chymotrypsin/PMSF only control. The concentrations of active MMPs were determined by active-site titration against TIMP-1 or TIMP-2 in a peptide cleavage assay using the quenched fluorescent peptide Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH~2~(Dpa is *N*3-(2,4-dinitrophenyl)-[l]{.smallcaps}-2--3-diaminopropionyl). *In vitro* chemokine cleavage assays with recombinant MMPs were performed in 50 m[m]{.smallcaps} Tris, 200 m[m]{.smallcaps} NaCl, 5 m[m]{.smallcaps} CaCl~2~, pH 7.4, for 16 h at 37 °C. Initially, an enzyme to substrate molar ratio of 1:10 was assessed to screen for cleavage activity followed by lower enzyme concentrations to 1:1000 to suggest biological relevance. Cleavage assay products were analyzed as above by MALDI-TOF MS and confirmed by silver-staining after 15% Tris-Tricine SDS-PAGE. Chemokine cleavage was defined to be positive when the MS spectra showed a cleavage product with a greater than 20% ion intensity of the full-length chemokine.

For kinetic analysis CCL15 was incubated with increasing molar ratios of each of the MMPs. Gels of the reaction products were stained with Coomassie Brilliant Blue R-250, and bands were quantified by densitometry using Alpha-imager software and the results fitted to the equation *k*~cat~/*K~m~* = (ln 2)/*Et*½).

#### Cells

Human CCR1-transfected B300-19 (PreB) cells were kindly provided by Dr. B. Moser (Cardiff, UK) and cultured in RPMI 1640 supplemented with 10% fetal bovine serum, 2 m[m]{.smallcaps} glutamine, 50 μ[m]{.smallcaps} β-mercaptoethanol, and 1.5 μg/ml puromycin. The human monocytic cell line, THP-1 (ATCC), were grown in RPMI 1640 supplemented with 10% fetal bovine serum.

#### Calcium Mobilization

Calcium mobilization of THP-1- or CCR1-transfected B300-19 cells was evaluated as previously described ([@B40]). Briefly, 1 × 10^7^ cells/ml were loaded with 2 μ[m]{.smallcaps} Fluo-4-acetoxymethyl ester (Molecular Probes) for 30 min at 37 °C, 5% CO~2~ in RPMI 1640 media supplemented with 1% fetal bovine serum. Cells were washed 3 times and resuspended at 1 × 10^6^ cells/ml in fresh assay buffer (Ca^2+^/Mg^2+^-free Hanks\' balanced salt solution (Invitrogen), 20 m[m]{.smallcaps} HEPES, 2.5 m[m]{.smallcaps} probenecid (Sigma), 0.1% bovine serum albumin (BSA)). Assays were performed on 6.5 × 10^5^ cells in 800-μl cuvettes on an LS50B spectrofluorimeter (PerkinElmer Life Sciences) in time-drive mode with excitation and emission at 494 and 515 nm, respectively. Calibration was made by the addition of 5 μ[m]{.smallcaps} ionomycin (Sigma) followed by 1 m[m]{.smallcaps} MnCl~2~ (FisherBiotech) to determine *F*~max~ and *F*~min~, respectively. Absolute Ca^2+^ was calculated as *K~d~* × ((*F* − *F*~min~)/(*F*~max~ − *F*)) where the *K~d~* of Fluo-4 was 345 n[m]{.smallcaps} (Molecular Probes). Experiments were carried out in duplicate and repeated a minimum of three times. Statistical significance of cleaved *versus* full-length chemokines was evaluated by two-tailed *t* test in Prism (GraphPad).

#### Transwell Migration

The chemotactic response of THP-1 or CCR1-transfected B300-19 cells was evaluated ([@B40]). Chemokine or MMP and buffer controls, diluted in BSA-supplemented RPMI 1640, in the lower chamber were separated from 2 × 10^5^ cells/ml in the upper chamber of a 96-well Boyden chamber (Neuroprobe) by a 5 μ[m]{.smallcaps} pore filter. Assays performed at 37 °C, 5% CO~2~ were 90 min for THP-1 and 3 h for CCR1-transfected cells. Non-migrating cells were aspirated, and the upper chamber was washed with 2 m[m]{.smallcaps} EDTA. After transfer to a Maxisorb 96-well plate, the DNA content of the lower chamber was determined by CyQuant reagent (Invitrogen). The chemotactic index was calculated by the ratio of the relative fluorescence of samples from cells migrating in response to chemokine compared with the media control. Experiments were carried out in quadruplicate and repeated a minimum of three times. Statistical significance of cleaved *versus* full-length chemokines were evaluated by 2-way analysis of variance and Bonferroni post-test.

#### Glycosaminoglycan Binding

HiTrap^TM^ cation exchange Sepharose or heparin-Sepharose (GE healthcare) 1-ml columns were washed and equilibrated before loading 25 μg of full-length or cleaved chemokine in 1 ml of 10 m[m]{.smallcaps} potassium phosphate, pH 7.5. Using an Akta Purifier (Amersham Biosciences), columns were washed with 10 × *V~t~* of 10 m[m]{.smallcaps} potassium phosphate and then a linear gradient of 0 to 1.5 [m]{.smallcaps} NaCl over 30 min at a flow rate of 1 ml/min and monitored by in-line absorbance at 215 nm. ASCII files were imported into Prism (GraphPad) and normalized against base line. The effects of soluble GAGs, namely heparan sulfate and chondroitin sulfate A, B, and C (Seikagaku), on the *in vitro* cleavage of CCL16 by MMP-12 were assessed with a chemokine to GAG ratio of 1:5 (w/w) at an enzyme to substrate ratio of 1:25 (w/w).

RESULTS
=======

### 

#### Synovial Fluid Processing of CCL15

The key role of MMPs in processing chemokines is now well established, including the activation of CXC chemokines critical for neutrophil recruitment. However, an activating cleavage of CC chemokines by MMP activity was hitherto unknown. To evaluate the protease classes responsible for CCL15 processing *in vivo* ([@B20]), a pool of synovial fluids from eight arthritic patients ([Fig. 1](#F1){ref-type="fig"}*A*) was combined with full-length CCL15 ([Fig. 1](#F1){ref-type="fig"}*B*) and then incubated in the absence ([Fig. 1](#F1){ref-type="fig"}*C*) or presence ([Fig. 1](#F1){ref-type="fig"}, *D--G*) of protease inhibitors for 16 h at 37 °C. Endogenous synovial fluid proteases process CCL15 to products with spectral peaks detected by MALDI-TOF ([Fig. 1](#F1){ref-type="fig"}*C*) having *m*/*z* values of 7066, 7438, 7553, and 7766. In addition to the previously observed product CCL15-(25--92) in synovial fluid ([@B20]), we found additional cleavages of CCL15 to produce the products CCL15-(28--92), CCL15-(24--92), and CCL15-(22--92) ([Fig. 1](#F1){ref-type="fig"}*G*).

![**Synovial fluid MMP and serine proteases cleave CCL15.** Synovial fluid (SF) from eight rheumatoid arthritis patients was pooled, and 25-μg samples were incubated with 2.5 μg of CCL15 in the absence or presence of protease inhibitors for 16 h at 37 °C. Mass spectra are shown of C18 ZipTip prepared samples after 16 h of incubation of SF (*A*), CCL15-(1--92) (*B*), SF + CCL15 (*C*), SF + CCL15 + marimastat (*D*), SF + CCL15 + PMSF (*E*), and SF + CCL15 + marimastat + PMSF (*F*). *G*, cleavage products were assigned by MALDI-TOF mass by comparison of measured with predicted mass to charge ratios (*m*/*z*) with a +1 charge ionization (\[M + H\]^+^). *H*, cleavage was visualized on silver-stained 15% Tris-Tricine gels. *T1*, TIMP-1; *T2*, TIMP-2; *M*, marimastat; *P*, PMSF.](zbc0061295140001){#F1}

Two spectral peaks corresponding to CCL15-(28--92) (*m*/*z* 7066) and CCL15-(25--92) (*m*/*z* 7,738) were eliminated by the metalloproteinase inhibitors TIMP-1, TIMP-2, or marimastat ([Fig. 1](#F1){ref-type="fig"}*D*). Thus, these cleavage products are due to MMP activity. In the presence of PMSF, the peak corresponding to CCL15-(24--92) (*m*/*z* 7553) was eliminated, and that for CCL15-(22--92) (*m*/*z* 7766) was significantly reduced ([Fig. 1](#F1){ref-type="fig"}*E*), showing a role for serine proteases *in vivo*. CCL15-(24--92) and -(22--92) were previously shown to result from cathepsin G ([@B20]) and neutrophil elastase activity ([@B20], [@B41]), respectively. Pepstatin or leupeptin had no effect on processing of CCL15, revealing that neither cysteine nor carboxyproteases cleaved the chemokine (not shown).

In the presence of both marimastat and PMSF, CCL15 remains intact in synovial fluid ([Fig. 1](#F1){ref-type="fig"}*F*). Together, these results suggest that neutrophil serine proteases and MMPs are responsible for CCL15 processing *in vivo*. Moreover, the presence of two products when one protease class is inhibited implies that processing by one protease family is not dependent upon another. The proteolytic activity in synovial fluid was impressive as a 10-fold excess of CCL15 on a weight for weight basis was fully cleaved ([Fig. 1](#F1){ref-type="fig"}*H*).

#### Selective Processing of CCL15 by MMPs

To evaluate which MMPs could be responsible for CCL15 processing observed in synovial fluid, *in vitro* cleavage assays were performed. CCL15-(1--92) is processed at the amino terminus by all MMPs tested ([Fig. 2](#F2){ref-type="fig"}) and by high concentrations of MMP-7 at the carboxyl terminus. Interestingly, all MMPs processed CCL15-(1--92) to CCL15-(25--92), one of the two forms observed by MMPs present in synovial fluid ([Fig. 2](#F2){ref-type="fig"}*A*) and previously observed from recombinant production in insect cells ([@B42]). The second synovial fluid product, CCL15-(28--92), results from MMP-2, -3, -8, -9, -12, and -13 processing.

![**All MMPs evaluated precisely cleaved CCL15 at one or more sites.** Human CCL15-(1--92) was incubated with recombinant MMP-1, -2, -3, -7, -8, -9, -12, -13, and -14 for 16 h at 37 °C. *A*, cleavage products were assigned by MALDI-TOF MS by comparison of measured with predicted mass to charge ratios (*m*/*z*) with a +1 charge ionization (\[M + H\]^+^). Corresponding sequences are shown. *B*, cleavage assay products were visualized on silver-stained 15% Tris-Tricine gels. *C*, mass spectra of cleavage assay products of CCL15 in the absence (*left*) or presence (*right*) of MMP-12 show that the predominant truncated forms CCL15-(25--92) and -(28--92) are both present in the form used for functional assays.](zbc0061295140002){#F2}

By silver-stained gels the processing of CCL15 by MMP-9 appears minimal ([Fig. 2](#F2){ref-type="fig"}*B*), although both CCL15-(25--92) and CCL15-(28--92) cleavage products are observed on MALDI-TOF MS ([Fig. 2](#F2){ref-type="fig"}*A*). MMP-12 processing of CCL15-(1--92) results in complete truncation to two products as evident by MALDI-TOF MS ([Fig. 2](#F2){ref-type="fig"}*C*); this preparation was used for *in vitro* functional assays.

#### Kinetics Analysis of CCL15 Processing

MMP-12 most efficiently processed CCL15 ([Fig. 3](#F3){ref-type="fig"}), and with a rate of 3000 [m]{.smallcaps}^−1^s^−1^, this is \>100-fold faster than MMP-1, the least efficient MMP. Interestingly, two of the most efficient MMPs with the fastest rates were leukocyte-specific MMPs, macrophage MMP-12, and neutrophil MMP-8.

![**Kinetics of CCL15 processing by MMPs.** CCL15-(1--92) was incubated with increasing concentrations of recombinant MMP-1, -2, -3, -7, -8, -9, -12, -13, and -14 for 16 h and 37 °C at a 1:10 molar ratio. *A*, cleavage assay products were visualized on Coomassie Brilliant Blue R-250-stained 15% Tris-Tricine gels. *B*, *k*~cat~/*K~m~* was determined after densitometry of gels.](zbc0061295140003){#F3}

#### All Monocytic-responsive CC Ligands Are Processed by MMPs

To determine the novelty of MMP activation of CCL15, we next evaluated the MMP-processing capacity toward all monocyte chemoattractants in the CC chemokine subfamily, finding that every one of the CCR1, -3, -5, and -8 ligands was cleaved by one or more of the MMPs tested: MMP-1, -2, -3, -7, -8, -9, -12, -13, and -14 ([Table 1](#T1){ref-type="table"}). Of the 149 cleavage sites we sequenced in the 14 chemokines, 32 are new, being described for the first time, with 28 of these generating previously unidentified amino or carboxyl termini of the chemokines.

###### 

**MMP-truncation products of CC chemokines**

Chemokine truncation products after MMP cleavage were deconvoluted from MALDI-TOF MS spectra. The residue numbers of the resultant chemokine cleavage products are shown in parentheses. Sites in roman type represent novel cleavage sites; italics represent truncation sites previously identified. NC, indicates that the full-length chemokine was not cleaved by that MMP. ND, indicates that the cleavage site could not be determined. Activity of MMP-cleaved chemokine is based upon the information provided in footnotes.

  MMP Chemokine   1            2            3            7            8            9            12           13           14           Effect of cleavage
  --------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------------------------------------------------------------------------------------------------------------
  CCL1 (1--73)    NC           NC           (8--73)      (7--73)      NC           NC           (7--73)      (6--73)      NC           Unknown[*^a^*](#TF1-1){ref-type="table-fn"}
                                                         (7--70)                                                                       
  CCL2 (1--76)    (*5--76*)    *NC*         (*5--76*)    (*5--76*)    (*5--76*)    (*5--76*)    (*5--76*)    (*5--76*)    NC           Loss of agonist*^[b](#TF1-2){ref-type="table-fn"},[c](#TF1-3){ref-type="table-fn"}^*
                                                         (5--67)                                                                       
  CCL3 (1--70)    (1--47)      NC           NC           (9--63)      (16--64)     (16--64)     ND           (1--47)      NC           Loss of agonist*^[a](#TF1-1){ref-type="table-fn"},[d](#TF1-4){ref-type="table-fn"}^*
                                                         (1--47)                                                                       
  CCL4 (1--69)    (16--62)     (6--44)      (6--44)      (1--61)      (*7--69*)    (14--61)     (*7--69*)    NC           (6--44)      Monomerize*^[a](#TF1-1){ref-type="table-fn"},[b](#TF1-2){ref-type="table-fn"},[c](#TF1-3){ref-type="table-fn"}^*
                               (*7--69*)                 (6--69)                                                          (*7--69*)    
  CCL5 (1--69)    NC           NC           NC           (1--65)      NC           NC           NC           (5--69)      NC           Antagonist[*^b^*](#TF1-2){ref-type="table-fn"}
  CCL7 (1--76)    (*5--76*)    (*5--76*)    (*5--76*)    (*7--76*)    *NC*         (*5--76*)    (*5--76*)    (*5--76*)    (9--76)      Antagonist*^[b](#TF1-2){ref-type="table-fn"},[c](#TF1-3){ref-type="table-fn"}^*
                                                         (*5--76*)                                                        (*7--76*)    
                                                                                                                          (*5--76*)    
  CCL8 (1--76)    (*1--73*)    (*1--73*)    (*5--76*)    (*1--73*)    (*1--73*)    *NC*         (*7--76*)    (*1--73*)    (6--76)      Antagonist*^[b](#TF1-2){ref-type="table-fn"},[c](#TF1-3){ref-type="table-fn"}^*
                  (*5--73*)                              (*5--73*)    (*5--73*)                 (*1--73*)                 (*5--73*)    
                                                                                                (*5--73*)                 (*1--73*)    
  CCL11 (1--74)   NC           (10--74)     NC           (10--74)     NC           NC           (10--74)     NC           NC           Loss of agonist[*^d^*](#TF1-4){ref-type="table-fn"}
  CCL13 (1--75)   (*5--72*)    (*5--75*)    (*4--75*)    (6--75)      (*5--72*)    (*5--72*)    (*5--72*)    (*5--72*)    (*4--75*)    Antagonist*^[b](#TF1-1){ref-type="table-fn"},[c](#TF1-3){ref-type="table-fn"}^*
                                            (*5--75*)    (*4--75*)                                                                     
                                                         (*5--72*)                                                                     
  CCL14 (1--74)   NC           NC           NC           (1--70)      NC           NC           (1--71)      NC           NC           Increased agonist*^[a](#TF1-1){ref-type="table-fn"},[c](#TF1-3){ref-type="table-fn"}^*
                                                         (1--66)                                (4--72)                                
                                                                                                (*7--74*)                              
  CCL15 (1--92)   (*25--92*)   (14--92)     (17--92)     (17--88)     (25--92)     (*25--92*)   (*25--92*)   (*25--92*)   (14--92)     Increased agonist*^[b](#TF1-1){ref-type="table-fn"},[c](#TF1-3){ref-type="table-fn"}^*
                               (*25--92*)   (*25--92*)   (*17--92*)   (*28--92*)   (*28--92*)   (*28--92*)   (*27--92*)   (*27--92*)   
                               (*27--92*)   (*28--92*)   (*25--92*)                                          (*28--92*)                
                               (*28--92*)                                                                                              
  CCL16 (1--97)   (8--85)      (5--97)      (8--85)      (8--85)      (8--85)      (8--85)      (5--97)      (8--85)      (5--97)      Altered GAG binding
                               (8--77)                                             (8--77)      (8--85)      (8--77)      (8--85)      
                                                                                                (8--77)                                
  CCL17 (1--71)   NC           NC           NC           (4--69)      (9--71)      NC           (4--69)      (4--71)      NC           Unknown[*^a^*](#TF1-1){ref-type="table-fn"}
  CCL23 (1--99)   (11--99)     (11--99)     (11--99)     (11--99)     (11--99)     (11--99)     (11--99)     (28--99)     (14--99)     Increased agonist*^[b](#TF1-2){ref-type="table-fn"},[c](#TF1-3){ref-type="table-fn"}^*
                  (17--99)     (17--99)     (21--99)     (17--99)     (17--99)     (28--99)     (17--99)     (1--90)      (*30--99*)   
                  (23--99)     (26--99)     (26--99)     (23--99)     (26--99)                  (23--99)                               
                  (26--99)     (28--99)     (1--90)      (26--99)                               (26--99)                               
                  (28--99)                               (1--90)                                                                       
                  (*30--99*)                                                                                                           

*^a^* Unknown effect requiring further characterization.

*^b^* Predicted activity from studies reporting truncations at adjacent or nearby sites.

*^c^* Published known activity from protein engineering studies or characterization of cleavage at this site by other proteases.

*^d^* Predicted activity from reports of cleavages at homologous sites in homologous chemokines.

The broadest specificities observed are for MMP-7 and -12, which processed 14 and 13 chemokines, respectively. Unlike the other MMPs we used, MMP-7 and 12 lack a hemopexin C-domain. Although we have previously shown multiple examples where the hemopexin domain binds specific chemokines and increases cleavage, these results indicate that the hemopexin domain also restricts the substrate repertoire of MMPs. The processing of CCL2, -7, -8, and -13 by MMP-7 is in contrast to the absence of cleavage by MMP-7 we previously reported ([@B13]), which we attribute to improved quality control for the only commercially obtained MMP used.

Among the 32 novel truncation sites identified, this is the first report of any proteolysis of three chemokines: CCL1, CCL16, and CCL17. Although not investigated here, based upon the critical role of the amino termini in other CCL chemokines that have only 8--10 residues before the conserved cysteines ([@B7], [@B10], [@B12], [@B13], [@B15], [@B18], [@B43], [@B44]), we predict that the amino-terminal cleavages observed in CCL1 and CCL17 result in a similar loss of agonist activity of these chemokines. Similarly, the CCL5 (5--69) product produced by MMP-13 activity is also most likely to lose agonist activity similar to the CCL5-(3--69) and -(4--69) products previously evaluated ([@B15], [@B45]).

A novel amino-terminal truncation resulting in CCL11-(10--74) is observed after processing by MMP-2, -7, and -12. Unlike previously identified CCL11 truncations of two or three residues, which do not alter the chemoattractant potential ([@B46]), this MMP-processing is notable as it occurs between the two conserved cysteines at ^6^PTTC↓CFNL^13^, which are components of the two characteristic stabilizing disulfide bonds of the CCL chemokines. Almost certainly then, cleavage here will inactivate the chemokine through structural relaxation. Notably, this is a highly unusual cleavage site specificity unique among the MMPs and reveals that the active site of these MMPs can undergo rearrangement to accommodate the rigid disulfide-linked cysteine residues at P1 and P1′.

Herein, the first identification of both amino- and carboxyl-terminal proteolysis sites in CCL3 is identified. MMP-8 truncation of CCL3 was recently observed *in vivo* ([@B47]), although the site was not sequenced. We show that MMP-8 amino-terminally truncates CCL3-(1--70) to the product CCL3-(16--64), which is likely to be the site of the observed inactive *in vivo* product, likely through loss of receptor binding mediated via Phe^13^ ([@B48]). The related chemokine CCL4 is known to lose dimer affinity by removal of 5--8 amino-terminal residues ([@B49]), whereas the truncation product CCL4-(14--61) lacks activity ([@B48]). Thus, both are expected to occur after MMP cleavage of CCL4.

The CCL14-(7--74) product, here shown to result from MMP-12 processing, has been shown to enhance calcium mobilization ([@B50]). However, carboxyl-terminal truncations of the chemokine, observed here by MMP activity, have not previously been identified, and thus the functional effects of this require further investigation.

Although there was limited promiscuity of the MMPs toward chemokines, this was not observed with all chemokines. As was found for CCL15, CCL16 and CCL23 are most susceptible to processing, being cleaved by all MMPs evaluated. Moreover, multiple cleavage sites by a given MMP were observed. Therefore, these chemokine processing events were selected for further evaluation.

#### Selective Processing of CCL23 by MMPs

The 97-amino acid residue CCL23 is processed by all MMPs assessed at the amino terminus and at the carboxyl terminus by MMP-3, -7, and -13 ([Fig. 4](#F4){ref-type="fig"}, *A* and *B*). The detection of CCL23-(26--99) and the counterpart CCL23-(1--25) by MALDI-TOF MS after MMP-1, 2, 3, 7, 8, and -12 cleavage ([Fig. 4](#F4){ref-type="fig"}*A*) suggests that although multiple cleavages can occur within the first 25 residues of CCL23-(1--99), CCL23-(26--99) is the predominant stable end product. Similarly, both fragments resulting from cleavage of CCL23 by MMP-14 were observed, namely CCL23-(1--29) and CCL23-(30--99). CCL23-(30--99) is known to result from elastase and activity within synovial fluid ([@B20]), but we were unable to identify the protease classes present in synovial fluid responsible for CCL23 cleavage (results not shown). The CCL23-(26--99) preparation we used for *in vitro* functional assays lacks full-length chemokine as shown by MALDI-TOF MS ([Fig. 4](#F4){ref-type="fig"}*C*).

![**All MMPs evaluated precisely cleaved CCL23 at one or more sites.** Human CCL23-(1--99) was incubated with recombinant MMP-1, -2, -3, -7, -8, -9, -12, -13, and -14 for 16 h at 37 °C. *A*, cleavage products were assigned by MALDI-TOF MS by comparison of measured with predicted mass-to-charge ratios (*m*/*z*) with a +1 charge ionization (\[M + H\]^+^). Corresponding sequences are shown. *B*, cleavage assay products were visualized on silver-stained 15% Tris-Tricine gels. *C*, mass spectra of cleavage assay products of CCL23 in the absence (*left*) or presence (*right*) of MMP-12 show that the predominant truncated form CCL23-(26--99) is present in the form used for functional assays.](zbc0061295140004){#F4}

#### Selective Processing of CCL16 by MMPs

CCL16 is processed by MMPs at both the amino and carboxyl termini ([Fig. 5](#F5){ref-type="fig"}). This is the first identification of CCL16 proteolysis. A CCL16-(5--97) product was observed after MMP-2, -8, and -14 activity, and CCL16-(8--85) or -(8--77) were generated by all MMPs tested ([Fig. 5](#F5){ref-type="fig"}). By silver-stained gels the activity of MMP-1 appears minimal ([Fig. 5](#F5){ref-type="fig"}*A*), although a CCL16-(8--85) product was observed by MALDI-TOF MS ([Fig. 5](#F5){ref-type="fig"}*B*); the cleavage sites are shown in [Fig. 5](#F5){ref-type="fig"}*C*. Conversely, MMP-14 degrades CCL16, yet both the CCL16-(5--97) and (8--85) products represent a \>20% intensity in the mass spectra (not shown), indicating that these are likely the initial cleavage products. For *in vitro* functional assays we used MMP-12 at a 1:10 molar ratio with CCL16 to result in complete truncation of CCL16 to two products by MALDI-TOF MS ([Fig. 5](#F5){ref-type="fig"}*D*).

![**All MMPs evaluated precisely cleaved CCL16.** Human CCL16-(1--97) was incubated with recombinant MMP-1, -2, -3, -7, -8, -9, -12, -13, and -14 for 16 h at 37 °C. *A*, cleavage assay products were visualized on silver-stained 15% Tris-Tricine gels. *B*, cleavage sites were assigned by MALDI-TOF MS by comparison of measured with predicted mass-to-charge ratios (*m*/*z*) with +1 charge ionization (\[M + H\]^+^). *C*, cleavage sites of each MMP are shown on the CCL16 sequence. *D*, mass spectra of cleavage assay products of CCL16 in the absence (*left*) or presence (*right*) of MMP-12 show that the predominant truncated forms CCL16-(8--77) and -(8--85) are both present in the form used for functional assays.](zbc0061295140005){#F5}

#### Calcium Mobilization in CCR1-transfected B300-19 and THP-1 Cells in Response to MMP-processed CCL15 and CCL23

MMP-cleaved chemokines induced a significant calcium flux after CCL15-(25--92, 28--92) and CCL23-(26--99) treatment of human CCR1-transfected B300-19 cells ([Fig. 6](#F6){ref-type="fig"}*A*). With no activity observed by full-length CCL15 and CCL23, this shows that MMPs activate these two chemokines. To confirm this surprising result, similar experiments were performed using THP-1 cells ([Fig. 6](#F6){ref-type="fig"}*B*); again, MMP-processed chemokines caused a concentration-dependent increase in THP-1 cell intracellular calcium mobilization, whereas a very minor response to CCL15-(1--92) and CCL23-(1--99) only occurred at the highest concentration evaluated ([Fig. 6](#F6){ref-type="fig"}*C*). Notably, calcium mobilization did not occur after stimulation with the 19-mer peptide corresponding to CCL23-(5--23). Finally, MMP-processing of CCL16 did not alter calcium mobilization (not shown).

![**MMP-mediated cleavages of CCL15 and CCL23 activates chemokine agonism.** Calcium mobilization (*A--C*) and chemotactic potential (*D--E*) of CCL15 and CCL23 are enhanced by MMP processing. *A* and *B*, representative traces of calcium flux, shown as a burst in relative fluorescence units (*RFU*) after the addition of 10 n[m]{.smallcaps} of full-length or MMP-truncated chemokine in CCR1-transfected B300-19 (*A*) and THP-1 cells loaded with Fluo-4 calcium indicator reagent (*B*). *C*, shown is the calcium mobilization dose response of THP-1 cells wherein calcium concentrations were calculated from relative fluorescence based on calibration with ionomycin and MnCl~2~. Transwell migration of CCR1-transfected B300-19 for 3 h (*D*) or THP-1 cells for 90 min (*E*) toward full-length or truncated chemokine through a 5-μm pore-sized filter is shown. Migrated cells were quantified by CyQUANT assay and displayed as chemotactic index, defined as the ratio of cells migrating in response to stimulus compared with buffer control. Results shown are the mean ± S.E. of three or more biological replicates of experiments completed in quadruplicate. Statistical analysis was by two-way ANOVA with Bonferroni post-test; the levels of significance comparing full-length to MMP-cleaved counterpart are: \*, *p* \< 0.05; \*\*, *p* \< 0.01; \*\*\*, *p* \< 0.001.](zbc0061295140006){#F6}

#### Chemotactic Response of CCR1 Transfectants and THP-1 Cells to MMP-processed CCL15 and CCL23

We mechanistically confirmed the calcium mobilization results by chemotaxis assays. Consistent with the Ca^2+^ flux results, both CCR-1-transfected B300-19 and THP-1 cells had a concentration-dependent response, with the characteristic hyperbolic curve to CCL15-(25--92, 28--92) and CCL23-(26--99) but notably with only a minimal response to intact CCL15 and CCL23 ([Fig. 6](#F6){ref-type="fig"}, *D* and *E*). The response of THP-1 cells to CCL15-(25--92, 28--92) was highest at 1 n[m]{.smallcaps} and thus was considerably more potent than CCL7 ([Fig. 6](#F6){ref-type="fig"}*E*). Indeed, equivalent chemotactic potential of cleaved CCL15 was only observed at a 10-fold higher concentration of CCL7, a prodigal monocyte chemoattractant. The 19-mer peptide corresponding to CCL23-(5--23) did not have chemotactic potential for THP-1 cells ([supplemental Fig. S1](http://www.jbc.org/cgi/content/full/M111.314609/DC1)). MMP-processing of CCL16 did not alter the Transwell migration compared with full-length CCL16 (not shown).

#### Heparin Binding Affinity of CCL16 Is Increased by MMP Processing

Given the role of chemokine carboxyl termini in GAG binding, we hypothesized that cleavage of the carboxyl terminus of CCL16-(1--97) would reduce GAG binding of the MMP-truncated chemokine compared with the full-length counterpart. The binding of MMP-12-processed chemokine CCL16-(8--77, 8--85) compared with intact CCL16-(1--97) was characterized using heparin-Sepharose chromatography ([Fig. 7](#F7){ref-type="fig"}*A*). Surprisingly, the truncated CCL16 has greater affinity for heparin-Sepharose, reproducibly eluting at 0.71 [m]{.smallcaps} *versus* 0.52 [m]{.smallcaps} NaCl for the intact molecule. To control for charge effects, equivalent experiments were performed with a strong cation exchange Sepharose column ([Fig. 7](#F7){ref-type="fig"}*B*). CCL16-(1--97) eluted at 0.51 [m]{.smallcaps} NaCl, whereas CCL16-(8--77, 8--85) reproducibly eluted at 0.56 [m]{.smallcaps} NaCl. The shift in elution on the strong cation exchange column was not as marked as on the heparin column, suggesting heparin specificity and that the interaction of specific amino acid residues or their spatial arrangement and not charge alone is responsible for the increased GAG binding by the chemokine. As previously observed for CXCL11 ([@B8]), soluble GAGs had no effect on the processing of CCL16 by MMP-12 ([Fig. 7](#F7){ref-type="fig"}*C*), showing that cleavage occurs of both soluble and GAG-bound full-length chemokine without masking of the cleavage site.

![**Heparin binding is enhanced upon CCL16 processing.** Shown are elution profiles of CCL16-(1--97) and MMP-cleaved CCL16-(8--77, 8--85) from heparin-Sepharose column (*A*) or strong cation exchange column (*B*). The absorbance at 215 n[m]{.smallcaps} was measured during a 30-ml gradient that reached 1.5 [m]{.smallcaps} NaCl. *C*, CCL16-(1--97) was incubated with recombinant MMP-12 in the presence of heparan sulfate (*HS*), chondroitin sulfate A (CSA), CSB, or CSC in 5-fold excess (w/w) for 16 h at 37 °C. Cleavage assay products were visualized on silver-stained 15% Tris-Tricine gels.](zbc0061295140007){#F7}

DISCUSSION
==========

We report the first instance of MMP-processing of CC chemokines that results in enhanced monocyte recruitment specifically by selective activation cleavages of CCL15, CCL16, and CCL23. Notably, these three chemokines are distinguished from other chemokines by the presence of uniquely long amino- or carboxyl-terminal sequences. Hence, these terminal peptides are responsible for chemokine latency, functioning as propeptides, and requiring their proteolytic removal for signaling that is 10-fold more potent than by CCL7. Together with previous findings for activation cleavages of CXC chemokines for neutrophil chemotaxis ([@B16], [@B27], [@B28]), it is now apparent that both macrophages and neutrophils have the potential to be recruited by MMP-activating cleavages of select chemokines in the right proteolytic milieu *in vivo*. Indeed, cleavage of CCL15 occurred *ex vivo* as determined by MALDI-TOF MS analysis of chemokine cleavage products in pooled synovial fluid from arthritis patients.

In addition to MMPs, serine proteases were also capable of cleaving CCL15 *ex vivo* as also found by Berahovich *et al.* ([@B20]). Notably, the macrophage-specific MMP-12 was kinetically the most efficient in CCL15 activation ([Fig. 3](#F3){ref-type="fig"}), suggesting it potentially contributes to a feed-forward mechanism of monocyte recruitment. Overall, the two most efficient MMPs with the highest kinetic rates *in vitro* were leukocyte-specific MMP-12 and neutrophil-specific MMP-8. Finally, we also found that MMP-12 cleaved the classically regarded monocyte chemoattractants, namely CCL2, -7, -8, and -13, to generate products known to be CCR1, -2, and -3 receptor antagonists ([@B12], [@B13]). Together with the cleavage and inactivation by MMP-12 of all seven CXCL chemokines involved in neutrophil chemoattraction ([@B21]), this reveals an important role for the macrophage in dampening the cellular response in inflammation.

In showing that MMPs can activate select CCL chemokines, this reveals pleiotropic roles for MMPs in monocyte recruitment. Previous studies have shown the MMP-generated antagonist forms of CCL2, -7, -8, and -13 to be crucial in the resolution of inflammation by the active termination of monocyte recruitment ([@B12], [@B13]). Moreover, we recently found another crucial role for MMPs where genetic ablation of neutrophil MMP-8 delayed neutrophil apoptosis leading to massive and prolonged inflammatory infiltrates in tissue ([@B51]). This study reveals both the selectivity of MMP proteolytic roles and further complexity in the exquisite pleiotropic regulation of inflammation.

By the addition of protease inhibitors, we determined that both MMP and serine proteases generate stable CCL15 cleavage products in human arthritic synovial fluid. Neutrophil elastase cleaves CCL15 to a (22--92) product ([@B20]) that we also found, whereas cathepsin G processing results in products of (24--92, 27--93, and 29--92) ([@B20], [@B41]), rendering these neutrophil proteases as likely candidates responsible for the additional cleavages we observed. Interestingly, previous studies using PMN supernatant did not identify the CCL15-(25--92) product ([@B20], [@B41]) that was observed here. Although all MMPs are capable of processing CCL15 *in vitro*, the *in vivo* response may be specific to one or just a few MMPs due to other factors such as limited expression, interactors, or localization. Indeed, although several MMPs are capable of processing murine CXCL5/LIX *in vitro*, MMP-8 cleavage of the chemokine is critical *in vivo* and is not compensated for by elevated neutrophil MMP-9, which also cleaves at the same site as MMP-8 in the *Mmp8*^−/−^ mouse ([@B16]).

These results suggest the utilization of two new mechanisms for monocyte recruitment: enhanced haptotactic gradient formation and the generation of potent receptor agonists with increased chemotactic potential that can now be formally tested in appropriate *in vivo* models. A distinctive feature of CCL16, CCL15, and CCL23 is proteins size; at 97, 92, and 99 amino acids in length, respectively, they are much longer than typical chemokines that consist of 65--80 amino acids. The carboxyl terminus of CCL16 extends 44 amino acids after the conserved fourth cysteine residue, whereas CCL15 and CCL23 have extended amino termini of 31 and 32 amino acids, respectively. Also, unlike all other chemokines evaluated, these three chemokines were cleaved by all MMPs tested ([Table 1](#T1){ref-type="table"}), suggesting that the extended termini, most likely showing structural disorder, increases their susceptibility to proteolysis and, hence, possibilities for proteolytic regulation. Indeed, truncated forms of both CCL15 and CCL23 were previously observed during recombinant chemokine protein expression in heterologous cells ([@B35], [@B52], [@B53]).

Select chemokines also have increased activity after dipeptidyl peptidase, cathepsin, urokinase-type plasminogen activator, and chymase proteolysis ([@B20], [@B23], [@B32]), and synthetic CCL15-(25--92) increases Ca^2+^ mobilization ([@B53]--[@B55]), yet ours is the first study to identify MMP-activation. This was shown for MMP-cleaved CCL15 by calcium mobilization in THP-1 cells ([Fig. 6](#F6){ref-type="fig"}, *B* and *C*) through CCR1 activity ([Fig. 6](#F6){ref-type="fig"}*A*). Similarly, CCL23-(26--99) enhances Ca^2+^ mobilization in both THP-1- and CCR1-transfected B300-19 cells ([Fig. 6](#F6){ref-type="fig"}, *A--C*). This was reflected by an elevation in chemotactic response to MMP-processed CCL15 and CCL23 by CCR1-transfectant ([Fig. 6](#F6){ref-type="fig"}*D*) and THP-1 ([Fig. 6](#F6){ref-type="fig"}*E*) cells.

Previous studies of another subfamily of chemokines, the neutrophil chemoattractants CXCL5 and CXCL8, have shown that MMP processing of the amino termini results in products with 10-fold higher chemotactic potential than the full-length counterpart ([@B16], [@B28], [@B56], [@B57]). Although these neutrophil chemoattractants do not have an extended amino terminus like CCL15 and CCL23, the precise processing and maintenance of the critical ELR sequence enables CXCR2 activation. As for neutrophil recruitment where only two of the seven ELR^+^ CXCR2 binding human chemokines are activated by proteolysis, a similar limited proteolytic selectivity for just two CCL chemokines suggests the importance of proteolysis in the control of monocyte and macrophage recruitment under certain, but not all circumstances.

The cleavage patterns are complex and differ even between closely related chemokines in the same species and between species due to sequence diversity. Indeed, unlike human CCL7 ([@B12], [@B13]), murine CCL7 is not cleaved to an antagonist at position 4↓5 by MMPs (not shown). Because we have specifically studied human chemokine cleavage by human MMPs and there are no homologous murine chemokines for CCL15, CCL16, and CCL23, confirmatory studies in murine models of inflammation will be difficult to interpret. However, the presence of amino-terminal truncation forms of CCL15 and CCL23 in rheumatoid arthritis was recently shown through the use of antibodies ([@B20]); the carboxyl termini, but not amino termini, of truncated CCL15 and CCL23 were identified in synovial fluid. Although neither the exact truncation sites nor the proteases responsible could be identified, Berahovich *et al.* ([@B20]) showed that synovial fluid cleaved CCL15-(1--92) to a (25--92) product *in vitro*. We now show the broad ability of MMPs in cleaving CCL15 at ^22^VLN↓SFH^27^ by MMP-1, -2, -3, -7, -8, -9, -12, and -13 ([Fig. 2](#F2){ref-type="fig"}). Notably, cleavage at this position by the small S1′ pocket MMPs 1 and 7 is unexpected due to the large serine residue at P1′, thereby indicating conformational plasticity in the protease active site upon substrate interaction. This was also indicated by the unusual cleavage of CCL11 at an expected very rigid and structurally complex region of the chemokine at ^9^C↓C^10^ by MMPs, which also has not been previously described.

The situation is different for the long carboxyl-terminal chemokine CCL16 where MMP processing neither altered the chemotactic response nor Ca^2+^ mobilization in THP-1 cells, as compared with full-length chemokine (not shown). This supports the findings of Howard *et al.* ([@B58]), who describe the chemotactic potential of CCL16 as minimal. Indeed, we found that a chemotactic response toward CCL16 was only observed at concentrations \>10 n[m]{.smallcaps}, but this is obtainable after MMP cleavage leading to enhanced GAG binding in tissues.

Immobilization on the cell surface and presentation to circulating leukocytes through high affinity interactions with GAG side chains of proteoglycans are critical for the *in vivo* activity of many chemokines ([@B2]). By creating a high, localized concentration of chemokine, the haptotactic gradient provides the directionality for leukocytes as well as potentially placing the chemokine in an optimal orientation for chemokine-receptor interactions ([@B59]). Disruption of haptotactic gradients by proteolysis of the proteoglycan core protein decreases chemotaxis ([@B60]), and MMP-truncation of the Th1 cell chemokine CXCL11 reduces GAG binding efficiency ([@B8]). In contrast, we observed increased GAG binding upon MMP processing of CCL16 to CCL16-(8--77, 8--85). Removal of 12 and 20 carboxyl-terminal residues may expose or lead to rearrangement of previously buried residues to form stronger interactions with the heparin used in our analysis. Specifically, the residues ^47^KRNR^50^, which correlate with the signature GAG binding motif BB*X*B (where B represents a basic amino acid) that is found in other CC chemokines ([@B61]--[@B63]), may be exposed, resulting in increased GAG binding *in vitro* with a stronger haptotactic gradient formed *in vivo* to promote monocyte migration.

In addition to the identification of the truncated chemokine forms of CCL23 by MALDI-TOF MS, the cleaved amino termini CCL23-(1--25) and -(1--29) were identified ([Fig. 4](#F4){ref-type="fig"}*A*). This suggests that the amino terminus is released as a complete segment and, therefore, may have functionality. The amino terminus of CCL15 between residues Asp^4^ to Leu^23^ is 89.5% homologous and 94.7% similar to CCL23 ([supplemental Fig. S1](http://www.jbc.org/cgi/content/full/M111.314609/DC1)), suggesting that functionality within this peptide may be shared between these two chemokines. The alternatively spliced chemokine CCL23β contains an insert of 18 amino acids between Asp^24^↓Phe^25^, termed SHAAGtide, which is chemotactic for both monocytes and neutrophils through FPRL1 binding ([@B64]). In contrast to SHAAGtide, CCL23-(5--23) did not chemoattract THP-1 cells or isolated peripheral blood neutrophils nor did it alter THP-1 cell chemotaxis to CCL7 ([supplemental Fig. S1](http://www.jbc.org/cgi/content/full/M111.314609/DC1)). Furthermore, in three different assays the peptide had no antibacterial properties against *Escherichia coli* or *Staphylococcus aureus*, although we were unable to confirm the antimicrobial activities of CCL15-(1--92) previously published ([@B65]) (not shown). Finally, CCL23-(5--23) did not activate THP-1 cells or neutrophils as assayed by reactive oxygen species production and degranulation, respectively (not shown). Like SHAAGtide, CCL23-(5--23) was proteolytically processed *in vitro*, with cleavage sites comparable with those observed for CCL23 ([supplemental Fig. S1](http://www.jbc.org/cgi/content/full/M111.314609/DC1)). The exception is MMP-14 cleavage of CCL23-(5--23) to -(11--23) and not the -(14--99) product observed in full-length chemokine, suggesting that additional sites within the full-length chemokine modify the MMP cleavage preference. This may be due in part to exosite interactions of the MMP and chemokine that sterically hinder access by MMP-14 to Phe^10^--Met^11^. Such unexpected negative substrate selectivity has also been found in the selectivity of MMPs in cleaving CCL2 and CCL7 ([@B66]).

In identifying the proteases responsible for CCL15 cleavage in synovial fluid, which could not be done before ([@B20]), our work adds to the importance of MMPs in regulating chemokine activity. The presence of four CCL15 truncation variants after processing by synovial fluid suggests that serine proteases and MMPs work in concert as part of the protease web ([@B30]). Furthermore, processing by one protease family is not dependent upon another given the presence of two products when one class of proteases was inhibited. In homeostasis or acute inflammation, protease activity is tightly regulated by latency as a zymogen, by localization, and by endogenous inhibitors, and so a single protease or class may be responsible for normal function. In synovial fluid used here, the proteolytic activity was significant, completely processing a 10-fold excess of chemokine compared with total protein in the fluid. This suggests that in chronic disease many regulation mechanisms are overcome and, thus, multiple proteases can contribute to disease progression through redundant processing of chemokines. Together with the absence of homologous chemokines in mouse, such redundancy renders specific *in vivo* validation difficult, and indeed our several attempts to do this in various systems did not provide conclusive *in vivo* confirmation.

In our previous work we proposed a model whereby macrophages produce MMP-12, which terminates neutrophil recruitment ([@B21]). We now build upon that model and suggest that MMPs, with an important but not exclusive contribution by macrophage MMP-12, act in a positive feed-forward mechanism to process CCL15, CCL16, and CCL23, which has potential to promote monocyte recruitment. Our study also suggests that the long amino- and carboxyl-terminal chemokines CCL16, CCL15, and CCL23 are expressed as prochemokines. Upon stimulation of an inflammatory response, the associated increased activity of MMPs together with serine proteases ([@B20], [@B41]) results in precise truncations of the full-length chemokines to promote leukocyte chemoattraction through improved gradient formation or receptor activation. Collectively then, MMPs have the potential to regulate all limbs of the recruitment and dissipation phases of neutrophils and macrophages in inflammation.
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